AzurRx BioPharma is a biotechnology business based in the US. AzurRx BioPharma shares (AZRX) are listed on the NASDAQ and all prices are listed in US Dollars. AzurRx BioPharma employs 12 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $4.94 |
| 200-day moving average | $7.50 |
| Wall St. target price | $16.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-15.49 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $N/A from 2021-12-08
| 1 week (2024-08-26) | N/A |
|---|---|
| 1 month (2024-08-02) | N/A |
| 3 months (2024-06-02) | N/A |
| 6 months (2024-03-02) | N/A |
| 1 year (2023-09-02) | N/A |
|---|---|
| 2 years (2022-09-02) | N/A |
| 3 years (2021-09-03) | -100.00% |
| 5 years (2019-09-06) | -100.00% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -233.79% |
| Return on equity TTM | -1271.87% |
| Profit margin | 0% |
| Book value | $0.85 |
| Market Capitalization | $34.4 million |
TTM: trailing 12 months
We're not expecting AzurRx BioPharma to pay a dividend over the next 12 months.
AzurRx BioPharma's shares were split on a 1:10 basis on 12 September 2021. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AzurRx BioPharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for AzurRx BioPharma shares which in turn could have impacted AzurRx BioPharma's share price.
Over the last 12 months, AzurRx BioPharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AzurRx BioPharma's is 1.5109. This would suggest that AzurRx BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
AzurRx BioPharma, Inc. , a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc.
Use this calculator to quickly see potential outcomes of your options trades.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.